Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma

Table 1 Studies in which Nucleoside analogues were administered after treatment for hepatitis B virus-related hepatocellular carcinoma

Authors	Treated vs Untreated	Treatment	Observation time	HCC Tx	Recurrence	Survival
Kubo et al[27]	14 vs 10	LVD	1117 d	Ope	NA	Tumor-free survival
			(median)			(P = 0.0086)
Kuzuya et al[28]	16 vs 33	LVD	38.0 mo vs 32.6 mo	Ope/RFA	NS	NS
			(median)		(P = 0.622)	(P = 0.623)
Li et al[29]	43 vs 36	LVD with/without ADV	12 mo	Ope	NS	Overall survival
					(P = 0.077)	(P = 0.0094)
Piao et al[30]	30 vs 40	LVD	24 mo	Ope/RFA	NS	NS
						(P = 0.12)
Wu et al[31]	518 vs 4051	LVD/ETV/Telbivudine	2.64 yr	Ope	P < 0.001	P < 0.001

HCC: Hepatocellular carcinoma; LVD: Lamivudine; ETV: Entecavir; ADV: Adefovir-dipivoxil; NS: Not significant; NA: Not analyzed; Tx: Treatment.

Table 2 Studies on the effects of interferon on hepatitis B virus-related hepatocellular carcinoma after treatment

Authors	Treated vs Untreated	Treatment	Observation time	HCC Tx	Recurrence	Survival
Someya et al[38]	11 vs 69	IFNα	16 yr	Ope/RFA	P = 0.013 (High AST group)	NA
Lai et al[39]	35 vs 36	IFNα	30 mo	Inoperable	P = 0.001 (Tumor regression)	P = 0.047
Lo et al[40]	40 vs 40	IFNα	60 mo	Ope (Stage III/IVA)	P = 0.031	NS (P = 0.311)
Sun et al[41]	118 vs 118	IFNα	36.5 mo (median)	Ope	P = 0.048	P = 0.0003
Chen et al[42]	106 vs 109	IFNα	63.8 mo (median)	Ope	NS (P = 0.766)	NS (P = 0.826)

HCC: Hepatocellular carcinoma; IFN: Interferon; NS: Not significant; NA: Not analyzed; Tx: Treatment.